OncoMatch/Clinical Trials/NCT06707259
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
Is NCT06707259 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies anti-CD19 IL10/IL15 CAR-NK for b-cell non hodgkin lymphoma.
Treatment: anti-CD19 IL10/IL15 CAR-NK — To study the safety and effectiveness of cord blood-derived IL-10/IL-15 CD19-CAR NK in patients with B-cell non-Hodgkin's lymphoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 overexpression (positive)
The puncture section of the tumor tissue was positive for CD19 expression
Allowed: CD20 negative
Previous treatment must include CD20 monoclonal antibody treatment (unless the subject is CD20 negative)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: CD20 monoclonal antibody
Previous treatment must include CD20 monoclonal antibody treatment (unless the subject is CD20 negative)
Must have received: anthracycline
Previous treatment must include...anthracyclines
Cannot have received: gene therapy
Exception: allowed if >3 months prior
Have received gene therapy in the past 3 months
Cannot have received: other drugs that target CD19
Have any other drugs that target CD19
Lab requirements
Kidney function
Creatinine clearance rate (Cockcroft-Gault method) ≥60 mL/min; Glomerular filtration rate >50 mL/min
Liver function
Alanine aminotransferase, aspartate aminotransferase ≤ 2.5× UNL; Serum total bilirubin and alkaline phosphatase ≤1.5× UNL
Cardiac function
Cardiac ejection fraction (EF) ≥50%
Sufficient organ function reserve: (1) Alanine aminotransferase, aspartate aminotransferase ≤ 2.5× UNL (upper limit of normal value); (2) Creatinine clearance rate (Cockcroft-Gault method) ≥60 mL/min; (3) Serum total bilirubin and alkaline phosphatase ≤1.5× UNL; （4）Glomerular filtration rate>50Ml/min Cardiac ejection fraction (EF) ≥50%; (5) Under natural indoor air environment, basic oxygen saturation>92% .
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06707259 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene therapy, other drugs that target CD19 disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages